Clinical Trial Update: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study of Brentuximab Vedotin with Lenalidomide and Rituximab in relapsed/refractory Diffuse Large B-Cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING